# Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

Study · id `cardio:ct-nct06183931` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06183931](<https://clinicaltrials.gov/study/NCT06183931>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06183931

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 1182 participants.

## Technical summary

Registry record NCT06183931. Randomized; quadruple masking; primary purpose treatment. Start 2024-01-11 (actual); primary completion 2027-12-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1182 participants (enrolled count; ClinicalTrials.gov record NCT06183931, source copy `cardio:ctgov-nct06183931-2026-10-22`, retrieved 2026-10-31)
- Started: 2024-01-11 (actual) (ClinicalTrials.gov record NCT06183931, source copy `cardio:ctgov-nct06183931-2026-10-22`, retrieved 2026-10-31)
- Primary completion: 2027-12-06 (anticipated) (ClinicalTrials.gov record NCT06183931, source copy `cardio:ctgov-nct06183931-2026-10-22`, retrieved 2026-10-31)
- Completion: 2028-04-05 (anticipated) (ClinicalTrials.gov record NCT06183931, source copy `cardio:ctgov-nct06183931-2026-10-22`, retrieved 2026-10-31)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Canada; China; Czechia; Denmark; France; Germany; Greece; Ireland; Israel; Italy; Japan; Netherlands; Norway; Poland; South Korea; Spain; Sweden; Switzerland; Taiwan; Türkiye; United Kingdom (ClinicalTrials.gov record NCT06183931, source copy `cardio:ctgov-nct06183931-2026-10-22`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06183931-2026-10-22`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
- Acronym: DepleTTR-CM
- Condition: Transthyretin Amyloid Cardiomyopathy
- Intervention (Drug): ALXN2220
- Intervention (Drug): Placebo
- Lead sponsor: Alexion Pharmaceuticals, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`)
- Registry lists this organization as the lead sponsor: Alexion Pharmaceuticals, Inc. (`cardio:org-alexion-pharmaceuticals-inc`)

## Provenance

Content hash: a9fcde2d9e1c1545dccfba2578b763c9cd31f8c5bce66f4b861ba874664f0556
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
